AR080222A1 - Productos terapeuticos que comprenden dispersiones placentarias vitalizadas - Google Patents

Productos terapeuticos que comprenden dispersiones placentarias vitalizadas

Info

Publication number
AR080222A1
AR080222A1 ARP110100509A ARP110100509A AR080222A1 AR 080222 A1 AR080222 A1 AR 080222A1 AR P110100509 A ARP110100509 A AR P110100509A AR P110100509 A ARP110100509 A AR P110100509A AR 080222 A1 AR080222 A1 AR 080222A1
Authority
AR
Argentina
Prior art keywords
placental
product
placental product
therapeutic
factors
Prior art date
Application number
ARP110100509A
Other languages
English (en)
Inventor
Timothy Jansen
Jaime Zerhusen
Jin-Qiang Kuang
Samson Tom
Dana Yoo
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Publication of AR080222A1 publication Critical patent/AR080222A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
    • C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly

Abstract

Producto placentario terapéutico fluido que comprende células de placenta y una dispersion placentaria que comprende factores placentarios. Las células de placenta y la dispersion placentaria derivan de tejido placentario. Un tejido placentario opcionalmente puede ser un amnios, corion, o un corion sin trofoblastos. El producto placentario de la presente invencion es util para tratar a un paciente con una lesion tisular (por ejemplo una herida o quemadura) mediante la aplicacion del producto placentario sobre la lesion. Reivindicacion 1: Un producto placentario terapéutico caracterizado porque comprende: células de placenta en al menos aproximadamente 10.000 por ml de producto placentario; y factores placentarios que comprenden una o más proteínas de matriz extracelular, uno o más inhibidores de proteasa, uno o más factores de crecimiento, uno o más factores angiogénicos, y una o más MMP. Reivindicacion 2: El producto terapéutico de la reivindicacion 1, caracterizado porque la una o más proteínas de matriz extracelular es fibronectina, el uno o más inhibidores de proteasa es una TIMP, el uno o más factores de crecimiento es un TGF, y el uno o más factores angiogénicos es bFGF. Reivindicacion 4: El producto terapéutico de la reivindicacion 2, caracterizado porque las células de placenta están en una cantidad de menos de aproximadamente 1.000.000 por ml de producto placentario, la fibronectina está en una concentracion de la menos 740 ng/m del producto placentario y menos de aproximadamente 361.000 ng/ml del producto placentario, la TIMP está en una concentracion total de TIMP de al menos 6.500 pg/ml del producto placentario y menos de aproximadamente 15.000 ng/ml del producto placentario, el TGF es TGFR1 en una concentracion de al menos 250 pg/ml del producto placentario y menos de aproximadamente 26.000 pgfml del producto placentario, el bFGF está en una concentracion de al menos 900 pg/ ml del producto placentario y menos de aproximadamente 47.000 pg/ml del producto placentario, y la MMP está en una concentracion total de MMP de al menos 13.000 pg/ml del producto placentario y menos de aproximadamente 1.000 ng/ml del producto placentario. Reivindicacion 8: Un producto placentario terapéutico caracterizado porque comprende: células de placenta en al menos aproximadamente 10.000 por ml de producto placentario y menos de aproximadamente 1.000.000 por ml de producto placentario; y factores placentarios que comprenden uno o más miembros del grupo que consiste en fibronectinas en una concentracion de al menos 740 ng/m del producto placentario y menos de aproximadamente 361.000 ng/ml del producto placentario, TIMP en una concentracion total de TIMP de al menos 6.500 pg/ml del producto placentario y menos de aproximadamente 15.000 ng/ml del producto placentario, TGFB1 en una concentracion de al menos 250 pg/ml del producto placentario y menos de aproximadamente 26.000 pg/ml del producto placentario, bFGF en una concentracion de al menos 900 pg/ ml del producto placentario y menos de aproximadamente 47.000 pg/ml del producto placentario, y MMP en una concentracion de MMP total de al menos 13.000 pg/mI del producto placentario y menos de aproximadamente 1.000 ng/mI del producto pIacentario. Reivindicacion 9: El producto placentario terapéutico de cualquiera de las reivindicaciones 1 a 8, caracterizado porque los factores placentarios son factores placentarios amnioticos. Reivindicacion 10: El producto placentario terapéutico de cualquiera de las reivindicaciones 1 a 8, caracterizado porque los factores placentarios son factores placentarios corionicos. Reivindicacion 15: El producto placentario terapéutico de cualquiera de las reivindicaciones 5 a 14, caracterizado porque los factores placentarios comprenden uno o más inhibidores de proteasa que se eligen del grupo que consiste en metaloproteinasas de matriz (TIMP), alfa-2 macroglobulinas, y trombospondinas. Reivindicacion 17: El producto placentario terapéutico de cualquiera de las reivindicaciones 5 a 16, caracterizado porque los factores placentarios comprenden uno o más factores angiogénicos que se eligen del grupo que consiste en VEGF y bFGF. Reivindicacion 21: El producto placentario terapéutico de cualquiera de las reivindicaciones 1 a 20, caracterizado porque las células de placenta se eligen del grupo que consiste en MSC, ESC, células progenitoras de mesénquima derivadas de placenta, células madres mesenquimatosas de placenta, fibroblastos, células epiteliales, y células mesenquimatosas de placenta. Reivindicacion 24: El producto placentario terapéutico de cualquiera de las reivindicaciones 1 a 23, caracterizado porque las células de placenta están criopreservadas. Reivindicacion 27: El producto placentario terapéutico de cualquiera de las reivindicaciones 1 a 26, caracterizado porque el producto placentario se administra a un sujeto que lo necesita y en donde la composicion del producto placentario terapéutico cambia después de la administracion. Reivindicacion 32: El método de la reivindicacion 30 o la reivindicacion 31, caracterizado porque el producto placentario terapéutico es autologo a un sujeto.
ARP110100509A 2010-02-18 2011-02-18 Productos terapeuticos que comprenden dispersiones placentarias vitalizadas AR080222A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33846410P 2010-02-18 2010-02-18
US33848910P 2010-02-18 2010-02-18
US36956210P 2010-07-30 2010-07-30

Publications (1)

Publication Number Publication Date
AR080222A1 true AR080222A1 (es) 2012-03-21

Family

ID=44476694

Family Applications (6)

Application Number Title Priority Date Filing Date
ARP110100505A AR080218A1 (es) 2010-02-18 2011-02-18 Productos de membranas corionicas inmunocompatibles
ARP110100506A AR080219A1 (es) 2010-02-18 2011-02-18 Productos de membranas corionicas inmunocompatibles
ARP110100507A AR080220A1 (es) 2010-02-18 2011-02-18 Productos de membranas amnioticas inmunocompatibles
ARP110100509A AR080222A1 (es) 2010-02-18 2011-02-18 Productos terapeuticos que comprenden dispersiones placentarias vitalizadas
ARP110100510A AR080223A1 (es) 2010-02-18 2011-02-18 Productos terapeuticos que comprenden dispersiones placentarias vitalizadas
ARP110100508A AR080221A1 (es) 2010-02-18 2011-02-18 Productos de membranas amnioticas inmunocompatibles

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ARP110100505A AR080218A1 (es) 2010-02-18 2011-02-18 Productos de membranas corionicas inmunocompatibles
ARP110100506A AR080219A1 (es) 2010-02-18 2011-02-18 Productos de membranas corionicas inmunocompatibles
ARP110100507A AR080220A1 (es) 2010-02-18 2011-02-18 Productos de membranas amnioticas inmunocompatibles

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP110100510A AR080223A1 (es) 2010-02-18 2011-02-18 Productos terapeuticos que comprenden dispersiones placentarias vitalizadas
ARP110100508A AR080221A1 (es) 2010-02-18 2011-02-18 Productos de membranas amnioticas inmunocompatibles

Country Status (6)

Country Link
US (23) US20110206776A1 (es)
EP (10) EP2536417B1 (es)
AR (6) AR080218A1 (es)
CA (7) CA2790333A1 (es)
ES (2) ES2665466T3 (es)
WO (6) WO2011103462A1 (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2408207A (en) * 2003-11-24 2005-05-25 Johnson & Johnson Medical Ltd Wound dressing for the controlled release of therapeutic agents comprising also an inhibitor of a protease enzyme & a linker group cleavable by such an enzyme
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
WO2007038686A2 (en) 2005-09-27 2007-04-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8372437B2 (en) 2006-08-17 2013-02-12 Mimedx Group, Inc. Placental tissue grafts
DE102007007664B3 (de) 2007-02-13 2008-03-27 Mokveld Valves B.V. Drosselventil
US8357403B2 (en) 2007-09-07 2013-01-22 Mimedx Group, Inc. Placental tissue grafts
US9301679B2 (en) 2007-11-01 2016-04-05 Dignity Health Method of detecting neurological disease
US8721081B2 (en) 2007-11-01 2014-05-13 Dignity Health Method of detecting neurological disease
US9480549B2 (en) 2008-04-25 2016-11-01 Allosource Multi-layer tissue patches
US9358320B2 (en) 2008-04-25 2016-06-07 Allosource Multi-layer tissue patches
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
WO2010101780A2 (en) * 2009-03-04 2010-09-10 Peytant Solutions, Inc. Stents modified with material comprising amnion tissue and corresponding processes
US20140286911A1 (en) 2013-03-15 2014-09-25 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
CA2790333A1 (en) 2010-02-18 2011-08-25 Osiris Therapeutics, Inc. Methods of manufacture of immunocompatible amniotic membrane products
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
WO2012003377A2 (en) * 2010-06-30 2012-01-05 Tissuetech, Inc. Methods of preparing chorion tissue and products derived therefrom
EP3311826B1 (en) 2011-02-14 2020-04-29 MiMedx Group, Inc. Micronized placental tissue compositions and methods for making and using the same
KR20190086033A (ko) * 2011-02-14 2019-07-19 미메딕스 그룹 인크. 바르톤 젤리로 이루어진 라미네이트된 조직 이식편 및 그것의 제조 및 사용 방법
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
EP2717888B1 (en) 2011-06-10 2020-09-09 Tissuetech, Inc. Methods of processing fetal support tissues
US8932805B1 (en) 2011-10-31 2015-01-13 BioDlogics, LLC Birth tissue material and method of preparation
US9162011B2 (en) 2011-12-19 2015-10-20 Allosource Flowable matrix compositions and methods
WO2013096659A1 (en) * 2011-12-20 2013-06-27 Cook General Biotechnology Llc Methods and compositions for storage of animal cells
US9416410B2 (en) * 2012-02-14 2016-08-16 Genetics Development Corporation Cutoff point delta Ct. method for HER2 PCR testing in breast cancer
US8961617B2 (en) 2012-03-08 2015-02-24 Liventa Bioscience, Inc. Amnion and chorion constructs and uses thereof in abdominal surgery
US20130236506A1 (en) * 2012-03-08 2013-09-12 AFcell Medical Amnion and chorion constructs and uses thereof in ob-gyn surgery
CA2880157C (en) 2012-08-15 2020-07-21 Mimedx Group, Inc. Reinforced placental tissue grafts and methods of making and using the same
US9943551B2 (en) 2012-08-15 2018-04-17 Mimedx Group, Inc. Tissue grafts composed of micronized placental tissue and methods of making and using the same
US8904664B2 (en) 2012-08-15 2014-12-09 Mimedx Group, Inc. Dehydration device and methods for drying biological materials
DK2897625T3 (da) 2012-09-10 2019-12-16 Univ Wake Forest Health Sciences Amnionmembran og anvendelse deraf til sårheling og tissue engineering-konstrukter
US9180145B2 (en) 2012-10-12 2015-11-10 Mimedx Group, Inc. Compositions and methods for recruiting and localizing stem cells
US8946163B2 (en) 2012-11-19 2015-02-03 Mimedx Group, Inc. Cross-linked collagen comprising metallic anticancer agents
US9155799B2 (en) 2012-11-19 2015-10-13 Mimedx Group, Inc. Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent
US10206977B1 (en) 2013-01-18 2019-02-19 Mimedx Group, Inc. Isolated placental stem cell recruiting factors
JP6545102B2 (ja) 2013-01-18 2019-07-17 ミメディクス グループ インコーポレイテッド 心病態を治療する方法
US20140212390A1 (en) * 2013-01-30 2014-07-31 NuTech Medical, Inc. Placental Membrane Preparation and Methods of Making and Using Same
US9616093B2 (en) * 2013-01-30 2017-04-11 NuTech Medical, Inc. Placental membrane preparation and methods of making and using same
WO2014120946A1 (en) * 2013-01-30 2014-08-07 NuTech Medical, Inc. Placental membrane preparation and methods of making and using same
US11077229B1 (en) 2013-03-08 2021-08-03 BioDlogics, LLC Implant coating composition and method of use
US9770472B1 (en) * 2013-03-08 2017-09-26 Brahm Holdings, Llc Organ jacket and methods of use
EP2968646B1 (en) 2013-03-13 2019-05-29 AlloSource Fascia fibrous compositions and methods for their use and manufacture
US10029030B2 (en) 2013-03-15 2018-07-24 Mimedx Group, Inc. Molded placental tissue compositions and methods of making and using the same
US20160379205A1 (en) 2013-03-15 2016-12-29 Apple Inc. Facilitating transactions with a user account using a wireless device
US10555897B1 (en) 2013-03-16 2020-02-11 Brahm Holdings Llc Cosmetic composition and methods of treatment
US9993506B1 (en) 2013-03-16 2018-06-12 BioDlogics, Inc. Methods for the treatment of degenerative disc diseases by human birth tissue material composition
US9795639B1 (en) 2013-03-16 2017-10-24 BioDlogics, LLC Methods for the treatment of erectile dysfunction by human birth tissue material compostion
US10039792B1 (en) * 2013-03-16 2018-08-07 Brahm Holdings, Llc Methods for the treatment of inflammation and pain using human birth tissue material composition
US9446142B2 (en) 2013-05-28 2016-09-20 Mimedx Group, Inc. Polymer chelator conjugates
WO2014191978A2 (en) * 2013-05-30 2014-12-04 Cells For Cells Chorion-derived mscs cells and conditioned media as inducer for angiogenesis application for the treatment of cardiac degeneration.
JP6512759B2 (ja) * 2013-08-19 2019-05-15 国立研究開発法人国立循環器病研究センター 羊膜間葉系細胞組成物の製造方法及び凍結保存方法、並びに治療剤
WO2015031681A1 (en) 2013-08-30 2015-03-05 Mimedx Group, Inc. Micronized placental compositions comprising a chelator
CN104560862B (zh) * 2013-10-14 2019-09-13 佛教慈济医疗财团法人 分离脂肪组织活细胞方法、医药组合物及其用途、细胞库
EP3076982B1 (en) 2013-12-06 2020-02-19 Allosource Method of drying sheets of tissue
EP3094336A4 (en) 2014-01-17 2018-02-14 MIMEDX Group Inc. Method for inducing angiogenesis
US9856454B2 (en) 2014-02-27 2018-01-02 Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Rapid mincing of adipose tissues to isolate live cells in vitro
WO2015171143A1 (en) * 2014-05-07 2015-11-12 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
JP2017514879A (ja) * 2014-05-07 2017-06-08 オシリス セラピューティクス，インコーポレイテッド 免疫適合性のある羊膜生成物
JP2017514876A (ja) * 2014-05-07 2017-06-08 オシリス セラピューティクス，インコーポレイテッド 治療用胎盤組成物、その製造法及び使用法
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
EP3185918B1 (en) 2014-08-28 2021-08-18 MiMedx Group, Inc. Collagen reinforced tissue grafts
WO2016044030A1 (en) 2014-09-19 2016-03-24 Osiris Therapeutics, Inc. Bone repair product and methods of use thereof
US20160095307A1 (en) * 2014-10-07 2016-04-07 NuTech Medical, Inc. Method and composition for hypothermic storage of placental tissue
US10201573B1 (en) 2014-10-27 2019-02-12 Brahm Holdings, Llc Human birth tissue material composition and methods for the treatment of damage associated with a cerebral vascular accident
US10265438B1 (en) 2014-11-03 2019-04-23 BioDlogics, LLC Methods and compositions for the repair and replacement of connective tissue
US10765705B2 (en) 2014-11-24 2020-09-08 Prime Merger Sub, Llc Visco-supplement compositions, and methods of use thereof
US20160287750A1 (en) * 2014-12-31 2016-10-06 Applied Biologics, Llc Standardized amniotic membrane tissue graft
WO2016138025A2 (en) 2015-02-23 2016-09-01 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
WO2016187555A1 (en) 2015-05-20 2016-11-24 Tissuetech, Inc. Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
WO2017025965A1 (en) * 2015-08-13 2017-02-16 Kamada Ltd. Compositions derived from cohn fraction paste and use thereof
WO2017112934A1 (en) * 2015-12-23 2017-06-29 Lifenet Health Decellularized placental membrane and methods of preparing and use thereof
CA3010904C (en) * 2016-01-08 2024-03-05 Cryolife, Inc. Human placental tissue graft products, methods, and apparatuses
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
JP7050692B2 (ja) 2016-03-14 2022-04-08 プラコウス セラピューティクス，インコーポレイテッド 無細胞胎盤調製物
CA3029253A1 (en) * 2016-06-24 2017-12-28 Osiris Therapeutics, Inc. Viable lyophilized compositions derived from human tissues and methods of making the same
EP3474869A4 (en) 2016-06-24 2020-01-08 Osiris Therapeutics, Inc. COMPOSITIONS DERIVED FROM HUMAN TISSUE AND USES THEREOF
CA3032160A1 (en) 2016-08-24 2018-03-01 Arthrex, Inc. Tissue hybrid for use in repairing, reconstructing or regenerating musculoskeletal degenerative processes or injuries
US10772986B2 (en) 2017-01-26 2020-09-15 Allosource Fascia fibrous compositions and methods for their use and manufacture
WO2018144694A1 (en) 2017-02-01 2018-08-09 Plakous Therapeutics, Inc. Placental tissue compositions
CN106834257B (zh) * 2017-03-23 2020-06-30 天晴干细胞股份有限公司 一种分离胎盘间充质干细胞混合酶及其分离方法
WO2018211486A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
CA3062123A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
CN107254431B (zh) * 2017-05-25 2020-08-18 林翠霞 一种新型组织工程皮肤制备方法
CN107296041B (zh) * 2017-07-02 2020-12-25 江西瑞济生物工程技术股份有限公司 一种新鲜羊膜保存液及新鲜羊膜保存方法与应用
JP2021502814A (ja) 2017-11-14 2021-02-04 クック・バイオテック・インコーポレイテッドＣｏｏｋ Ｂｉｏｔｅｃｈ Ｉｎｃｏｒｐｏｒａｔｅｄ 保存組織製品および関連する方法
CN107779429A (zh) * 2017-12-07 2018-03-09 陕西九州生物医药科技集团有限公司 一种人皮肤组织来源成纤维细胞快速分离培养方法
CN109652363A (zh) * 2018-11-13 2019-04-19 广东唯泰生物科技有限公司 胎盘壁蜕膜间充质干细胞分化为子宫内膜上皮细胞的方法
US11511017B2 (en) 2019-03-12 2022-11-29 Arthrex, Inc. Ligament reconstruction
CN110144322A (zh) * 2019-04-15 2019-08-20 湖南南华爱世普林生物技术有限公司 一种胎盘间充质干细胞快速分离与培养至收获冻存的方法
EP3955940A4 (en) * 2019-04-16 2023-01-04 Lifenet Health PRODUCTS DERIVED FROM GENITAL TISSUES AND PREPARATION AND USES THEREOF
CN110141686B (zh) * 2019-05-07 2021-11-02 吉林省海创生物科技有限公司 一种人脐带间充质干细胞注射液及其面部填充注射方法
CN110179679A (zh) * 2019-06-25 2019-08-30 贵州医科大学 含脐带间充质干细胞培养液提取物的生物养颜修护面膜精华、面膜及其制备方法
WO2021003257A1 (en) * 2019-07-01 2021-01-07 Auxocell Laboratories, Inc. Methods and compositions for collecting and using placental tissue cells and placental blood cells
WO2021123320A1 (en) * 2019-12-20 2021-06-24 Dr. Kalali Prof. Mostafazadeh Dipl. Ing. Miedl (Kmm) Gesellschaft Bürgerlichen Rechts A composition and its use for a universal therapy against tumor cells
WO2021183851A1 (en) * 2020-03-12 2021-09-16 Osiris Therapeutics, Inc. Human tissue derived compositions and uses thereof
WO2022074523A1 (en) 2020-10-06 2022-04-14 Osiris Therapeutics, Inc. Primed placental tissue and uses in regenerative medicine
WO2022098774A1 (en) 2020-11-06 2022-05-12 Smith & Nephew, Inc. Graft composite for hip labrum reconstruction
KR102523933B1 (ko) * 2021-05-03 2023-04-20 고려대학교 산학협력단 융모막 추출물로부터 분리된 엑소좀을 유효성분으로 포함하는 골형성 촉진용 약학적 조성물
WO2023150544A1 (en) * 2022-02-01 2023-08-10 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Simplified method of preparing cells for patient administration
WO2024020135A1 (en) * 2022-07-21 2024-01-25 Biostem Technologies, Inc. Collection and quantification of elements per square centimeter in a human placental membrane allograft

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8803697D0 (en) * 1988-02-17 1988-03-16 Deltanine Research Ltd Clinical developments using amniotic membrane cells
US5891617A (en) * 1993-09-15 1999-04-06 Organogenesis Inc. Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing
US6152142A (en) 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
US7331350B2 (en) 2000-02-11 2008-02-19 The General Hospital Corporation Photochemical tissue bonding
US7582292B2 (en) * 2000-02-26 2009-09-01 Artecel, Inc. Adipose tissue derived stromal cells for the treatment of neurological disorders
US20020039788A1 (en) 2000-02-29 2002-04-04 Isseroff Roslyn R. Corneal epithelial graft composites
US7504374B2 (en) * 2000-10-24 2009-03-17 Warsaw Orthopedic, Inc. Method for inducing deposition and maturation of bone comprising a co-therapeutic regimen of LMP-1 and BMP-2
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
NZ528035A (en) * 2001-02-14 2005-07-29 Robert J Hariri Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
EP1362095B1 (en) * 2001-02-14 2015-05-27 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
WO2002087424A2 (en) * 2001-05-02 2002-11-07 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
DE60233248D1 (de) * 2001-11-15 2009-09-17 Childrens Medical Center Verfahren zur isolierung, expansion und differenzierung fötaler stammzellen aus chorionzotte, fruchtwasser und plazenta und therapeutische verwendungen davon
US20070134261A1 (en) * 2001-12-03 2007-06-14 Hancock Robert E Effectors of innate immunity
US20030187515A1 (en) * 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
CA2483010A1 (en) * 2002-04-19 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Placental derived stem cells and uses thereof
WO2004032969A1 (en) * 2002-10-09 2004-04-22 Lorantis Limited Modulation of immune function
US7993922B2 (en) * 2002-10-18 2011-08-09 Reliance Life Sciences Pvt. Ltd. Three-dimensional tissue equivalent using macromass culture
US20060228339A1 (en) * 2003-06-16 2006-10-12 Zheng-Pin Wang Methods of preparing transplantable product for treatment of skin defects
WO2005038012A2 (en) * 2003-06-27 2005-04-28 Ethicon Incorporated Cartilage and bone repair and regeneration using postpartum-derived cells
WO2005021014A1 (fr) 2003-09-03 2005-03-10 Jiuchang Miao Preparation d'un amnios biologique conservable a temperature ambiante
DE602005020754D1 (de) * 2004-03-31 2010-06-02 Cook Inc Transplantatmaterial und gefässprothese mit extrazellulärer kollagenmatrix und dessen herstellungsverfahren
US7280326B2 (en) * 2004-07-30 2007-10-09 Hitachi Global Storage Technologies Netherlands B.V. Trilayer SAF with current confining layer
PL369552A1 (pl) 2004-08-12 2006-02-20 Sgp & Sons Ab Preparat farmaceutyczny lub/i żywieniowy lub/i laboratoryjny wzmagający, wspomagający funkcjonowanie komórek nerwowych i układu nerwowego oraz zastosowanie preparatu farmaceutycznego lub/i żywieniowego w procesie ochrony funkcji układu nerwowego oraz zastosowanie preparatu do ochrony wzrostu stymulacji namnażania i zapobiegania apoptozie komórek nerwowych
WO2006050213A2 (en) * 2004-10-29 2006-05-11 Michalow Alexander E Methods of promoting healing of cartilage defects and method of causing stem cells to differentiate by the articular chondrocyte pathway
WO2006051538A2 (en) * 2004-11-10 2006-05-18 Hadasit Medical Research Services And Development Ltd. Cells isolated from placenta, device for isolating same, and uses thereof
PL1831356T3 (pl) * 2004-12-23 2017-07-31 DePuy Synthes Products, Inc. Komórki poporodowe pochodzące z tkanki pępowinowej i sposoby ich wytwarzania i stosowania
WO2006088867A2 (en) * 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Method for expansion of stem cells
WO2006094247A2 (en) * 2005-03-02 2006-09-08 Tissuetech, Inc. Amniotic membrane extracts, compositions thereof, and methods of use
US20070015278A1 (en) * 2005-04-13 2007-01-18 Yuling Li Methods of isolating differentiable cells from placental-associated tissue and uses thereof
WO2007009062A2 (en) 2005-07-13 2007-01-18 Anthrogenesis Corporation Treatment of leg ulcers using placenta derived collagen biofabric
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
GB0514567D0 (en) * 2005-07-15 2005-08-24 Univ Nottingham Surgical membrane
EP1932549B1 (en) 2005-08-26 2016-12-28 AMNOS Co., Ltd. Dried amnion and method for drying treatment of amnion
WO2007038686A2 (en) * 2005-09-27 2007-04-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
EP2368973A1 (en) * 2005-10-13 2011-09-28 Anthrogenesis Corporation Production Of Oligodendrocytes From Placenta-Derived Stem Cells
PL2471904T3 (pl) * 2005-12-29 2019-08-30 Celularity, Inc. Populacje komórek macierzystych łożyska
US8455250B2 (en) * 2005-12-29 2013-06-04 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
US8871198B2 (en) * 2006-03-29 2014-10-28 Stemnion, Inc. Methods related to wound healing
US20070178159A1 (en) * 2006-01-30 2007-08-02 Alza Corporation In-Situ Forming Porous Scaffold
WO2007146106A2 (en) * 2006-06-05 2007-12-21 Cryo- Cell International, Inc. Procurement, isolation and cryopreservation of maternal placental cells
ZA200810412B (en) * 2006-06-09 2010-03-31 Anthrogenesis Corp Placental niche and use thereof to culture stem cells
WO2008021391A1 (en) * 2006-08-15 2008-02-21 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
US8372437B2 (en) 2006-08-17 2013-02-12 Mimedx Group, Inc. Placental tissue grafts
WO2008042441A1 (en) * 2006-10-03 2008-04-10 Anthrogenesis Corporation Use of umbilical cord biomaterial for ocular surgery
WO2008060377A2 (en) * 2006-10-04 2008-05-22 Anthrogenesis Corporation Placental or umbilical cord tissue compositions
CA3178363A1 (en) * 2006-10-06 2008-05-15 Celularity Inc. Human placental collagen compositions, and methods of making and using the same
CA2850793A1 (en) * 2006-10-23 2008-05-02 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
AU2008216749B2 (en) * 2007-02-12 2014-03-13 Celularity Inc. Treatment of inflammatory diseases using placental stem cells
JP5224250B2 (ja) 2007-02-23 2013-07-03 国立大学法人富山大学 医用代用膜
KR20080104844A (ko) * 2007-05-29 2008-12-03 포천중문의과대학교 산학협력단 태반-유래 영양막 줄기 세포의 분리방법
EP2014767A1 (en) * 2007-06-15 2009-01-14 Centro di Ricerca E. Menni T cell immunomodulation by placenta cell preparations
WO2008156659A1 (en) 2007-06-18 2008-12-24 Children's Hospital & Research Center At Oakland Method of isolating stem and progenitor cells from placenta
KR20220122774A (ko) * 2007-09-26 2022-09-02 셀룰래리티 인코포레이티드 인간 태반 관류액으로부터의 혈관형성 세포
EP2783692B1 (en) * 2007-09-28 2019-01-02 Celularity, Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
WO2009044408A1 (en) * 2007-10-03 2009-04-09 International Centre For Cardio Thoracic And Vascular Diseases (A Unit Of Frontier Lifeline Pvt. Ltd) A treated amniotic membrane and method of treating amniotic membrane
BRPI0821489A2 (pt) * 2007-12-27 2015-06-16 Ethicon Inc Tratamento de degeneração do disco intervetebral com o uso de células derivadas de tecido de cordão umbilical humano
AU2009228056B2 (en) 2008-03-27 2015-03-12 Biolife Solutions, Inc. Materials and methods for hypothermic collection of whole blood
CA2722475A1 (en) 2008-04-25 2009-10-29 Allosource Anti-adhesion barrier wound dressing comprising processed amniotic tissue and method of use
CN105796602A (zh) * 2008-08-20 2016-07-27 人类起源公司 利用分离的胎盘细胞治疗中风
WO2011074208A1 (ja) 2009-12-18 2011-06-23 国立大学法人東北大学 皮膚真皮又は羊膜透明化による角膜移植材料調製法
US20150010610A1 (en) 2010-02-18 2015-01-08 Osiris Therapeutics, Inc. Immunocompatible amniotic membrane products
US20150010506A1 (en) 2010-02-18 2015-01-08 Osiris Therapeutics, Inc. Therapeutic placental compositions, methods of making and methods of use
US20150010609A1 (en) 2010-02-18 2015-01-08 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
CA2790333A1 (en) 2010-02-18 2011-08-25 Osiris Therapeutics, Inc. Methods of manufacture of immunocompatible amniotic membrane products
US8632512B2 (en) 2010-04-09 2014-01-21 Kci Licensing, Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
JP2014115445A (ja) 2012-12-10 2014-06-26 Funai Electric Co Ltd 光学装置
WO2015171143A1 (en) 2014-05-07 2015-11-12 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
JP2017514879A (ja) 2014-05-07 2017-06-08 オシリス セラピューティクス，インコーポレイテッド 免疫適合性のある羊膜生成物
JP2017514876A (ja) 2014-05-07 2017-06-08 オシリス セラピューティクス，インコーポレイテッド 治療用胎盤組成物、その製造法及び使用法

Also Published As

Publication number Publication date
US20140301986A1 (en) 2014-10-09
EP2536824A1 (en) 2012-12-26
EP3351622A1 (en) 2018-07-25
US20180360886A1 (en) 2018-12-20
US9956248B2 (en) 2018-05-01
US20110212065A1 (en) 2011-09-01
US10272116B2 (en) 2019-04-30
US20230128936A1 (en) 2023-04-27
US11590172B2 (en) 2023-02-28
CA2790333A1 (en) 2011-08-25
EP3351625A1 (en) 2018-07-25
EP2536823A4 (en) 2014-04-30
CA2790340A1 (en) 2011-08-25
US20140127177A1 (en) 2014-05-08
US20110212063A1 (en) 2011-09-01
EP2536826A1 (en) 2012-12-26
AR080220A1 (es) 2012-03-21
US20230113145A1 (en) 2023-04-13
EP2536824A4 (en) 2014-04-30
US20200330520A1 (en) 2020-10-22
EP2536825A4 (en) 2014-05-07
AR080218A1 (es) 2012-03-21
US10258650B2 (en) 2019-04-16
US11590173B2 (en) 2023-02-28
ES2663720T3 (es) 2018-04-16
EP2536827B1 (en) 2018-01-10
US20110212158A1 (en) 2011-09-01
US20140127317A1 (en) 2014-05-08
US20200281981A1 (en) 2020-09-10
US11510947B2 (en) 2022-11-29
WO2011103470A1 (en) 2011-08-25
US11638725B2 (en) 2023-05-02
US10646519B2 (en) 2020-05-12
US20110212064A1 (en) 2011-09-01
EP2536826A4 (en) 2014-05-14
WO2011103472A1 (en) 2011-08-25
EP2536825A1 (en) 2012-12-26
EP2536824B1 (en) 2018-04-04
AR080219A1 (es) 2012-03-21
EP2536827A1 (en) 2012-12-26
WO2011103455A1 (en) 2011-08-25
US20210369784A1 (en) 2021-12-02
EP2536417A4 (en) 2014-05-07
ES2665466T3 (es) 2018-04-25
EP2536827A4 (en) 2014-06-11
AR080223A1 (es) 2012-03-21
EP2536826B1 (en) 2020-12-16
US20200000853A1 (en) 2020-01-02
US10576104B2 (en) 2020-03-03
EP3351624A1 (en) 2018-07-25
CA2790336A1 (en) 2011-08-25
CA2790322A1 (en) 2011-08-25
US20110206776A1 (en) 2011-08-25
EP2536417A1 (en) 2012-12-26
US20240050482A1 (en) 2024-02-15
EP2536417B1 (en) 2018-01-10
US20140294777A1 (en) 2014-10-02
WO2011103446A1 (en) 2011-08-25
EP2536823A1 (en) 2012-12-26
US20200069739A1 (en) 2020-03-05
EP3345998A1 (en) 2018-07-11
WO2011103451A1 (en) 2011-08-25
CA2790325A1 (en) 2011-08-25
CA2790436A1 (en) 2011-08-25
WO2011103462A1 (en) 2011-08-25
US20200230176A1 (en) 2020-07-23
AR080221A1 (es) 2012-03-21
US10265344B2 (en) 2019-04-23
US11207353B2 (en) 2021-12-28
US20110256202A1 (en) 2011-10-20
EP3351624B1 (en) 2022-09-14
EP2536825B1 (en) 2024-03-27
US20140140966A1 (en) 2014-05-22
US20230381241A1 (en) 2023-11-30
US20140037598A1 (en) 2014-02-06
CA3175739A1 (en) 2011-08-25
EP2536823B1 (en) 2017-12-20
EP3351622B1 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
AR080222A1 (es) Productos terapeuticos que comprenden dispersiones placentarias vitalizadas
Lin et al. Microenvironment‐protected exosome‐hydrogel for facilitating endometrial regeneration, fertility restoration, and live birth of offspring
Taghizadeh et al. Wharton’s Jelly stem cells: future clinical applications
US11446330B2 (en) Biologic preserving composition and methods of use
Kim et al. Enhanced wound healing effect of canine adipose-derived mesenchymal stem cells with low-level laser therapy in athymic mice
Gao et al. Improvement in the quality of heterotopic allotransplanted mouse ovarian tissues with basic fibroblast growth factor and fibrin hydrogel
Luan et al. Implantation of mesenchymal stem cells improves right ventricular impairments caused by experimental pulmonary hypertension
Du et al. Hypoxic conditioned medium of placenta-derived mesenchymal stem cells protects against scar formation
US20190314469A1 (en) Composition Comprising Thrombin-Treated Stem Cell-Derived Exosome For Treating Skin Wound
US20220031756A1 (en) Stem Cells for Wound Healing
Anitua et al. Biological effects of plasma rich in growth factors (PRGF) on human endometrial fibroblasts
WO2019126557A1 (en) Biologic preserving composition and methods of use
JP2017519050A (ja) 組織再生物質放出誘導型細胞治療剤組成物及びその製造方法
Dai et al. Both death receptor and mitochondria mediated apoptotic pathways participated the occurrence of apoptosis in porcine vitrified mii stage oocytes
KR20160149292A (ko) 면역적합성 융모막 생성물
AU2014393404A1 (en) Immunocompatible amniotic membrane products
KR101597604B1 (ko) 줄기세포의 보관 안정성 증진용 조성물
Zhang et al. Supplementation of mitochondria from endometrial mesenchymal stem cells improves oocyte quality in aged mice
Oyarzo et al. Bovine fetal mesenchymal stem cells obtained from omental adipose tissue and placenta are more resistant to cryoprotectant exposure than those from bone marrow
Freitas-Andrade et al. Acute connexin43 temporal and spatial expression in response to ischemic stroke
Schmidt et al. Effects of sulfur mustard on mesenchymal stem cells
Myung et al. A method for the activation of platelet-rich plasma via bead mill homogenizer for mesenchymal stem cell culture
WO2020252201A1 (en) Biologic preserving composition and methods of use
KR102191789B1 (ko) 저분자 화합물로 인한 인간 골수유래 중간엽 줄기세포 성장인자의 발현 제어 및 분비를 촉진하는 성장인자 대량 생산방법
KR102153635B1 (ko) 줄기세포 배양용 무혈청 배지 조성물 및 줄기세포의 배양방법

Legal Events

Date Code Title Description
FB Suspension of granting procedure